Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers

Journal of Clinical Pharmacology

Volumn 44, Issue 6, 2004, Pages 612-620

  Dvorchik, Barry ^a,b   Damphousse, David ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b Barry Dvorchik and Associates Inc   (United States)

Author keywords

Antibiotic therapy; Complicated skin and skin structure infections; Daptomycin; Elderly vs. young volunteers; Pharmacokinetics

Indexed keywords

DAPTOMYCIN;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; KIDNEY FUNCTION; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; RASH; VOMITING;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DAPTOMYCIN; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE;

EID: 2442650448     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004265646     Document Type: Article

References (14)

1. Fuchs PC, Barry AL, Brown SD: In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002;49:467-470.
2. Critchley IA, Draghi DC, Sahm DF, Thornsberry C, Jones ME, Karlowsky JA: Activity of daptomycin against susceptible and multidrug resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 2003;51:639-649.
3. Wesson KM, Lerner DS, Silverberg NB, Weinberg JM: Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Clin Dermatol 2003;21:64-69.
4. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, and Daptomycin 98-01 and 99-01 Investigators: The safety and efficacy of daptomycin in the treatment of complicated skin and skin structure infections. Clin Infect Dis; in press.
5. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL: Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001;45:845-851.
6. Woodworth JR, Nyhart EH, Brier GL, Wolny JD, Black HR: Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy subjects. Antimicrob Agents Chemother 1992;36:318-325.
7. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD: Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47:1316-1323.
8. Woodhouse K: The pharmacology of aging, in: Tallis R, Fillit H, Brochlehurst J (eds.), Geriatric Medicine and Gerontology. London: Harcourt Brace, 1998;169-178.
9. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1978;16:31-41.
10. Dvorchik B, Arbeit R, Chung J, Liu S, Knebel W, Kastrissios H: Population pharmacokinetic analysis of daptomycin. Antimicrob Agents Chemother; submitted for publication, 2003.
11. Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G: Pharmacokinetic and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 2002;46:31-33.
12. Use of population modeling to determine the tissue penetration of daptomycin and Monte Carlo simulation for determining the target attainment rate for a dose suitable for treatment of skin and skin structure infections. Cubist Internal Report, 2003.
13. Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, Eicer HG, et al: Impaired target site penetration of β-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001;29(2):385-391.
14. Tegeder I, Schmidtko A, Bräutigam L, Kirschbaum A, Geisslinger G, Lötsch J: Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002;71:325-333.